160 related articles for article (PubMed ID: 38335502)
1. ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.
Forster-Sack M; Zoche M; Pestalozzi B; Witzel I; Schwarz EI; Herzig JJ; Fansa H; Tausch C; Ross J; Moch H; Varga Z
J Pathol Clin Res; 2024 Mar; 10(2):e12362. PubMed ID: 38335502
[TBL] [Abstract][Full Text] [Related]
2. ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling.
Christgen M; Bartels S; Radner M; Raap M; Rieger L; Christgen H; Gluz O; Nitz U; Harbeck N; Lehmann U; Kreipe H
Genes Chromosomes Cancer; 2019 Mar; 58(3):175-185. PubMed ID: 30520184
[TBL] [Abstract][Full Text] [Related]
3. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
4. Genomic Characterization of Primary Invasive Lobular Breast Cancer.
Desmedt C; Zoppoli G; Gundem G; Pruneri G; Larsimont D; Fornili M; Fumagalli D; Brown D; Rothé F; Vincent D; Kheddoumi N; Rouas G; Majjaj S; Brohée S; Van Loo P; Maisonneuve P; Salgado R; Van Brussel T; Lambrechts D; Bose R; Metzger O; Galant C; Bertucci F; Piccart-Gebhart M; Viale G; Biganzoli E; Campbell PJ; Sotiriou C
J Clin Oncol; 2016 Jun; 34(16):1872-81. PubMed ID: 26926684
[TBL] [Abstract][Full Text] [Related]
5. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
[TBL] [Abstract][Full Text] [Related]
6. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
7. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
[TBL] [Abstract][Full Text] [Related]
8. E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements.
Christgen M; Bartels S; van Luttikhuizen JL; Bublitz J; Rieger LU; Christgen H; Stark H; Sander B; Lehmann U; Steinemann D; Derksen PWB; Kreipe H
Mod Pathol; 2020 Dec; 33(12):2483-2498. PubMed ID: 32572153
[TBL] [Abstract][Full Text] [Related]
9. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
10. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
[TBL] [Abstract][Full Text] [Related]
11. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
[TBL] [Abstract][Full Text] [Related]
12. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
Lien HC; Chen YL; Juang YL; Jeng YM
Breast Cancer Res Treat; 2015 Apr; 150(2):447-55. PubMed ID: 25773929
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic PIK3CA mutations in lobular breast cancer progression.
Christgen M; Noskowicz M; Schipper E; Christgen H; Heil C; Krech T; Länger F; Kreipe H; Lehmann U
Genes Chromosomes Cancer; 2013 Jan; 52(1):69-80. PubMed ID: 22997091
[TBL] [Abstract][Full Text] [Related]
14. Lobular breast cancer: Clinical, molecular and morphological characteristics.
Christgen M; Steinemann D; Kühnle E; Länger F; Gluz O; Harbeck N; Kreipe H
Pathol Res Pract; 2016 Jul; 212(7):583-97. PubMed ID: 27233940
[TBL] [Abstract][Full Text] [Related]
15. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.
Owens MA; Horten BC; Da Silva MM
Clin Breast Cancer; 2004 Apr; 5(1):63-9. PubMed ID: 15140287
[TBL] [Abstract][Full Text] [Related]
16. ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.
Deniziaut G; Tille JC; Bidard FC; Vacher S; Schnitzler A; Chemlali W; Trémoulet L; Fuhrmann L; Cottu P; Rouzier R; Bièche I; Vincent-Salomon A
Oncotarget; 2016 Nov; 7(45):73337-73346. PubMed ID: 27602491
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genetic and functional characterization of IPH-926: a novel CDH1-null tumour cell line from human lobular breast cancer.
Christgen M; Bruchhardt H; Hadamitzky C; Rudolph C; Steinemann D; Gadzicki D; Hasemeier B; Römermann D; Focken T; Krech T; Ballmaier M; Schlegelberger B; Kreipe H; Lehmann U
J Pathol; 2009 Apr; 217(5):620-32. PubMed ID: 19191266
[TBL] [Abstract][Full Text] [Related]
18. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
19. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
Ferguson DC; Momeni Boroujeni A; Zheng T; Mohanty AS; Ho AL; Arcila ME; Ross DS; Dogan S
Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
[TBL] [Abstract][Full Text] [Related]
20. Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.
Christgen M; Bartels S; Luft A; Persing S; Henkel D; Lehmann U; Kreipe H
Virchows Arch; 2018 Nov; 473(5):577-582. PubMed ID: 30094493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
